RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Ebola Voucher Bill Clears Senate, on Course to Become Law

Ebola Voucher Bill Clears Senate, on Course to Become Law

Posted 03 December 2014 | By Alexander Gaffney, RAC

Ebola Voucher Bill Clears Senate, on Course to Become Law

The US Senate has passed legislation that would overhaul the Neglected Tropical Disease Priority Review Voucher (PRV) system in the hopes of making it more enticing to pharmaceutical companies, and in particular those developing new treatments for the Ebola virus.

S.2917, the Adding Ebola to the FDA Priority Review Voucher Program Act, passed the US Senate by unanimous consent on 2 December 2013.

"Today the Senate took a strong step to support that mission by passing this bipartisan bill to incentivize the development of Ebola treatments and vaccines," Sen. Tom Harkin (D-IA) said in a statement. Sen. Lamar Alexander (R-TN) said he hoped the bill would "one day help lead to a cure" for Ebola.

For a complete explanation of the Ebola voucher reform bill, please see our explainer article here,

The bill now goes to the US House of Representatives, where an identical piece of legislation, H.R. 5729, was introduced on 18 November 2014 and already enjoys bipartisan support. If passed by the House Energy and Commerce Committee and the full House of Representatives, the bill would then be sent to President Barack Obama, who is expected to sign it.

In a blog post in November 2014, Obama's Ebola czar, Ron Klain, called the bill "encouraging" and said it was a welcomed bipartisan effort against the threat of Ebola.


US Senate Statement

Bill Tracker for S.2917


© 2022 Regulatory Affairs Professionals Society.